The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study

Hydroxychloroquine (HCQ) and chloroquine were found to have positive results in some non-randomized clinical trials with more benefit in decreasing the viral load of COVID-19. HCQ is a lysosomotropic and lipophilic drug that can penetrate cell membranes, and accumulates in the acidic lysosomes. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsuwaidan, Salem, Memish, Ziad A., Alaklobi, Faisal, Khan, Kholood, Alajami, Hamdan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case-controlled Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444382/
https://www.ncbi.nlm.nih.gov/pubmed/34545307
http://dx.doi.org/10.1016/j.amsu.2021.102867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444382/
https://www.ncbi.nlm.nih.gov/pubmed/34545307
http://dx.doi.org/10.1016/j.amsu.2021.102867

Ejemplares similares